ASX Announcements

Becoming a substantial holder
Positive topline results from Phase 3 trial in Rett syndrome
Neuren presenting at Bell Potter Healthcare Conference
Q3 2021 quarterly activity and cash flow report
Neuren receives feedback on IND for Phelan-McDermid syndrome
Change of Director's Interest Notice - D Angus
US patent to 2034 granted for Neuren's NNZ-2591 in autism
Change of Director's Interest Notice - J Harry
Change of Director's Interest Notice - J Pilcher
Change of Director's Interest Notice - P Davies